Autogenous vaccines are the vaccines prepared from cultures of microorganisms obtained from an individual and then used to immunize that same individual against further spread and progress of the same microorganisms. Vaccination of animals is an essential part of animal health management. Autogenous vaccines are most preferred for animal vaccination purposes as it helps to boost the immune system and keep animals safe from various bacterial and viral infections. Autogenous vaccines that are derived from bacterial strains, owing to their greater efficacy as compared to viral strains are expected to grow at the rapid pace in the forecasted period. Increasing prevalence of bacterial infections among animals, preference toward autogenous vaccines over antibiotics and increased funding and support for international animal disease eradication are likely to grow demand for autogenous bacterial vaccines in the forecasted period.
The inadequacy of vaccines to treat the rising number of rare infectious diseases in livestock and domestic animals is a major driver propelling the autogenous vaccines market growth in the forecast period. Antibiotics are inefficient in controlling and preventing contagious infections, thus autogenous vaccines are a good alternative. The acceptance of autogenous vaccines in the livestock industry is being boosted by improvements in animal health, reduced animal suffering, efficient food production, and a reduction in the demand for antibiotics. The growth of the autogenous vaccines market is aided by rising animal care spending and research and development initiatives in the veterinary biologics sector.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Europe autogenous vaccine market. In addition, complete analysis of changes on the Europe autogenous vaccine market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Europe economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
Autogenous vaccine market comprises of different market segment like strain type, end user and country.
The Europe autogenous vaccine market includes key segments like bacterial strain and viral strain. The bacterial strain owning to the highest market share in the Europe region. Owing to increasing rare bacterial infections among livestock and companion animals the demand for the bacterial strain vaccine is expected to dominate the market in the forecast period. Bacterial infections among animals, preference toward bacterial strain autogenous vaccines over antibiotics, and increased funding and support for international animal disease eradication are accelerating the demand for this segment. Thus Europe is said to be the leader in terms of adoption of autogenous vaccines as they are demanded by practicing veterinarians and by animal owners and they are quite widely used, mainly in Europe region due to increasing number of veterinarians in the region is propelling the demand for bacterial strain vaccine in the region.
The autogenous vaccine market finds its major end user in livestock farming companies, veterinary research institutes, veterinary clinics and hospitals. The veterinary clinics and hospitals segment dominates the market the factors that attributed to the growing clinics and also veterinary clinics offer preventative health care plans for pets in their care enhances the demand for this segment in the region. The autogenous vaccines market attributed to increase in the number of veterinary hospitals and rising government funding for animal healthcare is leading to the growth of veterinary clinics and hospitals segment in the region.
Europe digital pathology market is studied for the following countries like France, Germany, Italy, Spain and UK. The demand for autogenous vaccine market in region is due to the increase in the number of veterinary hospitals and rising government investments in animal healthcare. Based on the country UK is expected to dominate the market in the Europe autogenous vaccine market. UK is expected to gain major market share during the estimated time period. Due to increase in the acceptance of autogenous vaccine and the increasing number of veterinary hospitals is anticipated to witness the growth at significant pace during forecast period. Additionally, Germany followed by France is expected to witness the growth of autogenous vaccine market.
The key players in autogenous vaccine market are Boehringer Ingelheim International, Elanco Animal Health, Ceva (Ceva Biovac), Phibro Animal Health Corporation, UVAXX Pte Ltd, Bimeda, Deltamune Animal Health, Epitopix, Genova Labs, Newport Laboratories, Hygieia Biological Laboratories, Vaxxinova, Elanco Animal Health, Addison Biological Laboratory, Phibro Animal Health Corporation and LOHMANN TIERZUCHT GmbH among others.
October 2019: Ceva entered into a license agreement with ProBioGen AG for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR technology.
September 2019: Agri Labs (Huvepharma, Inc.) established a new fermentation plant in Peshtera, Southern Bulgaria. This increases Huvepharma’s total production capacity by 30%. Huvepharma now has flexibility to ferment its entire current product portfolio in one place, with additional capacity remaining to introduce new products to their range in the future.
April 2018: Pharmaq announced the production of fish vaccines at a development center in Suzhou, China. Pharmaq, now owned by Zoetis, and the parent company is also ramping up vaccine R&D for other species.
March 2018: Apiam acquired Passionate Vetcare, a regional veterinary clinic in the north west of Bendigo, to support the opening of Apiam’s Bendigo Emergency & Referral Centre for servicing in the Central Victorian region.
March 2018: Ceva launched innovative programs to promote the production of autogenous poultry vaccines by focusing on more sustainable production.
The report analyses the autogenous vaccine market based on segment like by strain, end user and country. The autogenous vaccine market includes key segments like bacterial strain and viral strain. The bacterial strain leads the market due to increasing prevalence of bacterial infections among animals, preference toward autogenous vaccines over antibiotics. The autogenous vaccine market finds its major end user in livestock farming companies, veterinary research institutes, veterinary clinics and hospitals. The veterinary clinics and hospitals segment dominates the market due to the growing clinics and veterinary clinics that offer preventative health care plans for pets care enhances the demand for the veterinary clinics in the region. By country the UK dominate the market due to increasing number of emergence of infectious diseases increase in the acceptance of autogenous vaccine and the increasing number of veterinary hospitals is anticipated witness the growth of the autogenous vaccine market in the Europe region. Also, Germany and France are expected to witness the growth of autogenous vaccine market The Europe autogenous vaccine market is studied for the following countries like France, Germany, Italy, Spain and UK.
Why to buy this report: